Cargando…

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

AIMS: To investigate whether effects on chronic kidney disease risk factors could explain the apparent reduction in kidney outcomes (composite of macroalbuminuria, doubling of serum creatinine, renal replacement therapy, or renal death), primarily driven by changes in albuminuria, after treatment wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mann, Johannes F. E., Buse, John B., Idorn, Thomas, Leiter, Lawrence A., Pratley, Richard E., Rasmussen, Søren, Vilsbøll, Tina, Wolthers, Benjamin, Perkovic, Vlado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453827/ https://www.ncbi.nlm.nih.gov/pubmed/34009708 http://dx.doi.org/10.1111/dom.14443

Ejemplares similares

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
por: Rossing, Peter, et al.
Publicado: (2023)

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
por: Vilsbøll, Tina, et al.
Publicado: (2018)

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
por: Verma, Subodh, et al.
Publicado: (2021)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
por: Aroda, Vanita R., et al.
Publicado: (2022)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
por: Alsugair, Hassan A., et al.
Publicado: (2021)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
por: Vilsbøll, Tina, et al.
Publicado: (2019)

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
por: Mann, Johannes F. E., et al.
Publicado: (2018)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
por: Thethi, Tina K., et al.
Publicado: (2020)

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
por: Strain, W. David, et al.
Publicado: (2022)

Acute Kidney Injury Associated With Semaglutide
por: Leehey, David J., et al.
Publicado: (2021)

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
por: Vilsbøll, Tina, et al.
Publicado: (2016)

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
por: Rodbard, H. W., et al.
Publicado: (2016)

New hypoglycemic agents and the kidney: what do the major trials tell us?
por: Smyth, Brendan, et al.
Publicado: (2018)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
por: Pratley, Richard E., et al.
Publicado: (2021)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
por: Kumar, K B Sharan, et al.
Publicado: (2022)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(−/−) and LDLr(−/−) Mice by a Mechanism That Includes Inflammatory Pathways
por: Rakipovski, Günaj, et al.
Publicado: (2018)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1h840cmljv9bba268eqk480rop